VITEK® 2: Healthcare

Optimizing Collection to Care

The VITEK® 2 system has everything healthcare laboratories need for fast, accurate microbial identification, and antibiotic susceptibility testing.

The innovative VITEK® 2 microbial identification system includes an expanded identification database, the most automated platform available, rapid results, improved confidence, with minimal training time.

The VITEK® 2 system next-generation platform provides greater automation while increasing safety and eliminating repetitive manual operations. The rapid response time means results can be provided more quickly than with manual microbial identification techniques.


The VITEK® 2 system offers:

  • Windows® based, user-friendly software
  • bi-directional interface
  • epidemiology report module
  • Advanced Expert System™ (AES) software for on-line result validation
  • a new generation of test cards
  • a comprehensive database

Automated systems:

  • VITEK® 2 XL
  • VITEK® 2 60
  • VITEK® 2 Compact 60
  • VITEK® 2 Compact 30
  • VITEK® 2 Compact 15


  • Microbial Identification - bacteria and yeast identification (ID)
  • Antibiotic susceptibility testing (AST) and resistance mechanism detection
  • Epidemiologic trending and reporting


The VITEK® 2 system can:

  • Reduce time to microbial identification and antibiotic susceptibility testing results
  • Offer an extensive identification and susceptibility menu
  • Reduce waste with a miniaturized card-format that measures 10 cm x 6 cm x 0.5 cm and weighs only 16 grams
  • Meet the needs of any size laboratory

VITEK® 2 systems use Advanced Colorimetry™, an identification technology that enables identification of routine clinical isolates. Advanced Colorimetry provides:

  • High discrimination between species
  • Low rate of multiple choice and misidentified species
  • Minimal number of off-line tests

The system includes an Advanced Expert System (AES) that analyzes MIC patterns and detects phenotypes for most organisms tested. This helps optimize laboratory efficiency for lean laboratory management. Rapid results allow clinicians to discontinue empiric therapy and prescribe targeted therapy, resulting in improved patient outcomes and enhanced antibiotic stewardship.

With its ability to provide accurate “fingerprint” recognition of bacterial resistance mechanisms and phenotypes, the Advanced Expert System (AES) is a critical component of VITEK® 2 technology.

VITEK® 2 technology with the Advanced Expert System™ offers:

  • Knowledge base developed from >100,000 references
  • >2,000 described phenotypes
  • >20,000 MIC distributions
  • >100 resistance mechanisms detected
  • >99 organisms
  • On average, provides a resulting range of five to seven MIC doubling dilutions per antibiotic
  • Extended MIC range to enable low-level resistance detection
  • Resistance-oriented results that highlight unusual phenotypes
  • Deduced antibiotic results to meet formulary requirements
  • Checks every result every time

Learn more about the synergy between VITEK® 2 and Etest™

Learn more about the synergy with LyfoCults® Quality Control Microorganisms



VITEK® 2 Automated Systems

VITEK® 2 is a fully automated system that performs bacterial identification and antibiotic susceptibility testing.

VITEK® 2 offers:

  • Intuitive software
  • User interface screen for immediate notification of system status to increase productivity.
  • Unique vacuum filler provides both safety and the highest level of automation.
  • Elimination of many manual steps:
    • Designed for simple temperature verification.
    • Completed tests are automatically ejected into an ergonomic trash container.

For larger volume labs, VITEK® 2 is available in two sizes: VITEK® 2 XL and VITEK® 2 60

VITEK® 2 Compact Automated Systems:

The VITEK® 2 Compact bacterial identification system, which is available in three sizes, brings VITEK® 2 technology to laboratories of every size. This instrument uses the same ID/AST cards, data management software and Advanced Expert System™ (AES) as the larger VITEK® 2 instrument.

The VITEK® 2 Compact features:

  • Three-step setup procedure
  • High level of automation
  • Intuitive, icon-driven software
  • Familiar Windows® format
  • Easy graphical representation of phenotypes
  • One-click result validation

Bringing VITEK® 2 productivity and automation to every laboratory

  • Proven VITEK® 2 Technology available for every size laboratory
  • Proven identifications using the same ID cards as the larger family of VITEK® 2 instruments
  • Easy training and implementation reduces training time with icon-driven, user-friendly Microsoft Windows®-based PC software
  • Improved workflow results in time, labor, and money savings
  • Peace-of-mind and increased confidence with AES, the only second-generation expert system available for antibiotic susceptibility testing
  • Rapid, reliable MIC susceptibility results

A compact design for optimal space savings:

  • Height: 24" (60 cm) / Width: 28" (72 cm)
  • Depth: 27" (68 cm) / Weight: 165 lbs (75kg)



  • Microbial Identification - bacteria and yeast identification (ID)
  • Antibiotic Susceptibility Testing (AST) and resistance mechanism detection
  • Epidemiologic trending and reporting

For Clinical Laboratory Professionals:

  • Most automated Microbial ID/Antibiotic Susceptibility Testing (AST) platform reduces set-up time and minimizes manual steps
  • Ergonomic workflow decreases the risk of repetitive motion injuries
  • Compact, sealed ID/AST cards enhance laboratory safety, minimizes waste and prevents biohazard spills
  • Rapid microorganism identification (ID)
  • Gram negative bacterial identification
  • Gram positive bacterial identification
  • Yeast identification
  • Neisseria, Haemophilus and other fastidious Gram negative bacteria identification
  • Anaerobic bacteria and coryneform bacteria identification
  • Rapid, same-day antimicrobial susceptibility testing (AST) increases microbiology’s relevance
  • VITEK® 2 and Etest meet a laboratory’s antimicrobial susceptibility testing (AST) needs and deliver minimum inhibitory concentrations (MICs) for most organisms
  • Gram negative antibiotic susceptibility testing (AST) cards
  • Gram positive antimicrobial susceptibility testing (AST) cards
  • Fluconazole antimicrobial susceptibility testing (AST) card for yeast susceptibility testing
  • Advanced Expert System (AES) automatically validates every result
  • Resistance detection by phenotype identification
  • Data management software and bidirectional interface with laboratory information system (LIS) allows for generation of epidemiology reports and antibiograms

For Clinicians and Administrators:

  • VITEK® 2 and Etest provides a complete antimicrobial susceptibility testing (AST) solution, with MIC results for bacteria and yeast, including slow-growing, fastidious and anaerobic bacteria
  • Rapid antibiotic susceptibility test (AST) results allow for early intervention in empiric antibiotic therapy
  • Rapid antimicrobial susceptibility testing (AST) results can improve patient outcomes
  • Rapid antimicrobial susceptibility testing (AST) results can decrease hospital length of stay and associated costs of prolonged hospitalization
  • Rapid antimicrobial susceptibility testing (AST) results allow for targeted antibiotic therapy
  • Rapid antimicrobial susceptibility testing (AST) results allow for de-escalation of empiric therapy
  • Targeted antibiotic therapy and de-escalation of empiric therapy improves antibiotic stewardship and reduces possibility of adverse drug events due to unnecessary therapy
  • Phenotypic analysis of every result improves resistance mechanism detection, validates susceptibility results and minimizes the possibility of erroneous results due to laboratory error
  • Wide range of minimum inhibitory concentration (MIC) values helps to guide antibiotic selection and dosing
  • Epidemiology reports include susceptibility trending information, organism occurrence and antibiogram generation
  • Provides rapid MIC results for Gram negative bacteria, Gram positive bacteria and yeast


The wide variety of VITEK® 2 identification cards (ID) and antibiotic susceptibility testing (AST) cards provides testing flexibility. This unique feature helps the laboratory control expenses and eliminates unnecessary testing.

The VITEK® 2 System and Test Cards originated with the NASA space program to identify infections in astronauts. This breakthrough innovation led to today’s VITEK® 2 technology.

The VITEK® 2 card is the size and shape of a playing card and contains 64 microwells. Each well contains identification substrates or antimicrobials. VITEK® 2 offers a comprehensive menu for the identification and antibiotic susceptibility testing of organisms.

The VITEK® 2 Test Card is sealed, which minimizes aerosols, splattering, spills, and personal contamination. Disposable waste is reduced by more than 80% over microtiter methods.

VITEK® 2 Test Cards offered


  • GN ID Card, Product number 21341
    • Gram negative bacterial identification
  • GP ID Card, Product number 21342
    • Gram positive bacterial identification
  • YST ID Card, Product number 21343
    • Yeast identification
  • NH ID Card, Product number 21346
    • Neisseria, Haemophilus and other fastidious Gram negative bacteria identification
  • ANC ID Card, Product number 21347
    • Anaerobic bacteria and coryneform bacteria identification

Download a menu of VITEK® 2 ID cards

Antibiotic Susceptibility Testing (AST)

  • Gram positive antimicrobial susceptibility testing (AST) cards
  • Gram negative antimicrobial susceptibility testing (AST) cards
  • Yeast antimicrobial susceptibility testing (AST) card

Go to the VITEK® 2 AST Configurator to determine which VITEK® 2 Card best meets your testing needs

Download the 2013 VITEK® 2 GN AST Card Grid

NEW: We are pleased to announce the launch of two new VITEK® 2 Gram Positive (GP) antibiotic susceptibility testing (AST) cards


PC-based software:

Intuitive, icon-driven software in a familiar Windows® format.

VITEK® 2 Advanced Expert System™ (AES):
Advanced Expert System™ (AES) analyzes MIC patterns and detects phenotypes for most organisms tested. This helps optimize laboratory efficiency for LEAN laboratory management.

VITEK® 2 Observa®:
Observa® is an information management system that stores the test data generated by the VITEK® 2 or VITEK® 2 Compact. The information is then gathered and formatted into many vital reports, including epidemiology and statistical reports. Additionally, data can be exported for analysis in other PC-based software programs. Not available for VITEK® 2 Compact 15. Click here to view a demo of OBSERVA.

Vitek® 2 PC5.01:
PC5.01 introduces new features to enhance efficiency and workflow. Multi user remote access, preliminary results, and new menu options have been shown to improve laboratory operations.
Read More

Quality Control:
This module provides your laboratory with the ability to store the VITEK® 2 Card Quality Control results and track quality control performance. Cumulative Quality Control reports are easily generated and can list all results with the exceptions flagged or list exceptions only.

Bi-directional Computer Interface (BCI):
With the Bi-directional Computer Interface (BCI) package, the VITEK® 2 can receive patient information directly from the Laboratory Information System and transmit microbiology test data directly to it. This minimizes keystrokes and data transcription errors while automatically uploading test data into the LIS. BCI plays an integrated role in providing rapid reporting of identification and antimicrobial susceptibility results.


Advanced Expert System™ Product Demo

OBSERVA® Product Demo

Superbugs Product Demo

What are Superbugs?
The Evolution of a Superbug.
Avoiding Superbugs.

Be Smart with Resistance

Initially discovered in the late 1950s, only 10 years after the birth of the first antibiotics, antibiotic-resistant bacteria, or "Superbugs," have become one of healthcare's biggest dilemmas. Once wrangled under control by the exciting new power of drugs like penicillin and tetracycline, Superbugs have learned to adapt and mutate to antibiotics, passing on their resistance to new generations, across species. With more than 110 million antibiotic prescriptions being written a year, doctors must find new ways to take on Superbugs, such as curbing antibiotic overuse and developing new technologies and drug-delivery systems.

bioMérieux provides in vitro diagnostics solutions for doctors so they can effectively treat patients. bioMérieux helps doctors determine whether or not to treat a patient with antibiotics and deliver susceptibility results on what may be the most effective antibiotic to use.

Microbes versus Humans*

Microbes 50,000,000,000,000,000,000,000,000,000,000
Humans 6,000,000,000
Microbes 50,000,000,000,000,000,000,000,000,000,000
Humans 6,000,000,000
Microbes 50,000,000,000,000,000
Humans 300,000,000
Microbes 30 minutes
Humans 30 years
Microbes 3,500,000,000
Humans 4,000,000


Schaechter M, et al., Microbiology in the 21st Centure Where are we and where are we going? ASM 2004.

Trivia Questions and Answers

False positive blood cultures have been show to increase length of stay. How much can this add to treatment costs?

a. $5

b. $50

c. $500

d. $5,000 CORRECT

Bates DW, Goldman L, Lee TH. Contaminant blood cultures and resources utilization: the true consequences of false- positive results. JAMA. 1991:265:365-369.
Each contaminated  blood culture results in about $6,000 extra in healthcare costs (JAMA 1991 265:365)
“One study shows that contaminated blood cultures can increase a patient's hospital stay by as much as 4.5 days and add more than $5,000 to the cost of treatment (adjusted for inflation since the study was published). (1,2)” From MLO article Controlling blood-culture contamination rates Medical Laboratory Observer, March, 2004   by Dennis J. Ernst


What organism is the leading cause of soft skin and tissue infections in the United States?

a. Healthcare Associated Methicillin Resistant Staphylococcus aureus

b. Community Associated Methicillin Resistant Staphylococcus aureus CORRECT

c. Streptococcus pyogenes



Rapidly characterizing coagulase-negative staphylococcus using PNA FISH® has been shown to decrease associated hospital costs by how much?

a. $4

b. $40

c. $400

d. $4,000 CORRECT

J Antimicrob Chemother. 2006 Jul;58(1):154-8. Epub 2006 Apr 24. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures.
Results:A total of 139 blood cultures positive with GPCC had PNAFISH results while 84 in the control group did not. Evaluable criteria were met in 53 patients in the PNA FISH group and 34 in the control group. When comparing the results obtained from using the PNA FISH assay with those for the control group, there was a significant reduction in median length of hospital stay from 6 to 4 days (P < 0.05, CI 0.95–1.87) and a trend towards less vancomycin usage with a decrease in associated hospital costs of _$4000 per patient.

A recent study has shown how many inpatients are impacted by Clostridium difficile?

a. 1 of 1,000

b. 5 of 1,000

c. 13 of 1,000


d. 50 of 1,000


HAIs have been shown to reduce net inpatient margins by how much?

a. $58

b. $508

c. $5,018



d. $50,180

APIC dispelling the Myths, the true cost of healthcare associated infections,

Pioneering diagnostics